Showing results (791-800 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|January 9, 2025
Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trialDan-Yun Ruan, Fu-Rong Liu, Xiao-Li Wei, et al.
The Lancet. Oncology|December 15, 2024
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trialIcro Meattini, Maria Carmen De Santis, Luca Visani, et al.
The Lancet. Oncology|December 5, 2024
Cancer education and training within the South Asian Association for Regional Cooperation (SAARC) countriesM Saiful Huq, Sandhya C Acharya, Simit Sapkota, et al.
The Lancet. Oncology|December 5, 2024
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challengesM Saiful Huq, Sandhya C Acharya, Saugat Poudyal, et al.
The Lancet. Oncology|December 9, 2023
Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trialJack Cuzick, Kim Chu, Brian Keevil, et al.
The Lancet. Oncology|December 15, 2023
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 studyEnrique Grande, José Á Arranz, Maria De Santis, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
The Lancet. Oncology|November 28, 2023
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trialsYu Fujiwara, Nobuyuki Horita, Elio Adib, et al.
The Lancet. Oncology|February 1, 2024
Current and projected gaps in the availability of radiotherapy in the Asia-Pacific region: a country income-group analysisDania Abu Awwad, Jesmin Shafiq, Geoffrey Paul Delaney, et al.
The Lancet. Oncology|January 13, 2024
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective studyMike M Sathekge, Ismaheel O Lawal, Chandrasekhar Bal, et al.
Pageof 336